Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business unit.